These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 17237677

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
    Shah GK, Sang DN, Hughes MS.
    Retina; 2009 Feb; 29(2):133-48. PubMed ID: 19202423
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [Abstract] [Full Text] [Related]

  • 9. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
    Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR.
    Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
    [Abstract] [Full Text] [Related]

  • 10. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Abrams P.
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group.
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
    Farah SE.
    Ophthalmic Surg Lasers Imaging; 2008 May; 39(4):294-8. PubMed ID: 18717434
    [Abstract] [Full Text] [Related]

  • 16. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
    Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs].
    Rodrigues EB, Rossi EE, Grumann Junior A, Meyer CH, Ho AC.
    Arq Bras Oftalmol; 2006 Jul; 69(5):756-65. PubMed ID: 17187150
    [Abstract] [Full Text] [Related]

  • 19. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F, Heiduschka P, Schraermeyer U, Tübingen Bevacizumab Study Group.
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.